These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 14564304)

  • 1. Matters of the heart: assessing the cardiovascular safety of new drugs.
    Konstam MA
    Am Heart J; 2003 Oct; 146(4):561-2. PubMed ID: 14564304
    [No Abstract]   [Full Text] [Related]  

  • 2. Life after Vioxx: the clinical implications.
    Fortun PJ; Hawkey CJ
    Hosp Med; 2005 May; 66(5):264-7. PubMed ID: 15920854
    [No Abstract]   [Full Text] [Related]  

  • 3. The lessons of Vioxx.
    Frazier KC
    N Engl J Med; 2005 Sep; 353(13):1420-1; author reply 1420-1. PubMed ID: 16192497
    [No Abstract]   [Full Text] [Related]  

  • 4. Trying times for painkiller choices. Vioxx, Bextra, and Celebrex can increase the risk for heart attack and other cardiovascular problems. So can the old standbys, like ibuprofen and acetaminophen.
    Harv Heart Lett; 2006 Oct; 17(2):1-3. PubMed ID: 17153752
    [No Abstract]   [Full Text] [Related]  

  • 5. Is rofecoxib safer than naproxen?
    Adelman A
    J Fam Pract; 2001 Mar; 50(3):204. PubMed ID: 11252204
    [No Abstract]   [Full Text] [Related]  

  • 6. The Vioxx debacle.
    Alpert JS
    Am J Med; 2005 Mar; 118(3):203-4. PubMed ID: 15745713
    [No Abstract]   [Full Text] [Related]  

  • 7. Does the pro-hypertensive effect of cyclooxygenase-2 inhibitors account for the increased risk in cardiovascular disease?
    Messerli FH; Sichrovsky T
    Am J Cardiol; 2005 Sep; 96(6):872-3. PubMed ID: 16169380
    [No Abstract]   [Full Text] [Related]  

  • 8. Cyclooxygenase-2 inhibitors and cardiovascular risk.
    Smith ER
    Can J Cardiol; 2005 Mar; 21(3):307-8. PubMed ID: 15776124
    [No Abstract]   [Full Text] [Related]  

  • 9. [COX-2 inhibitors--one step forward and two steps back].
    Evensen S; Spigset O; Slørdal L
    Tidsskr Nor Laegeforen; 2005 Apr; 125(7):875-8. PubMed ID: 15815733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Overestimated].
    Höer A; Häussler B
    Med Klin (Munich); 2006 Aug; 101(8):676-7; author reply 678-9. PubMed ID: 17051671
    [No Abstract]   [Full Text] [Related]  

  • 11. [Withdrawal of rofecoxib: a sign to be careful with coxibs in patients with increased cardiovascular risk].
    Bijlsma JW
    Ned Tijdschr Geneeskd; 2004 Oct; 148(44):2162-4. PubMed ID: 15559407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Slime fight in the lay media. Were the Vioxx fatal cases kept secret?].
    Zierenberg O
    MMW Fortschr Med; 2004 Oct; 146(43):60. PubMed ID: 15559526
    [No Abstract]   [Full Text] [Related]  

  • 13. The trade-off between cardiovascular and gastrointestinal effects of rofecoxib.
    Florentinus SR; Heerdink ER; de Boer A; van Dijk L; Leufkens HG
    Pharmacoepidemiol Drug Saf; 2005 Jul; 14(7):437-41. PubMed ID: 15937867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug safety. FDA panel urges caution on many anti-inflammatory drugs.
    Couzin J
    Science; 2005 Feb; 307(5713):1183-5. PubMed ID: 15731414
    [No Abstract]   [Full Text] [Related]  

  • 15. Discontinuation of Vioxx.
    Boers M
    Lancet; 2005 Jan 1-7; 365(9453):25-6; author reply 26-7. PubMed ID: 15639672
    [No Abstract]   [Full Text] [Related]  

  • 16. Discontinuation of Vioxx.
    Nyberg J
    Lancet; 2005 Jan 1-7; 365(9453):24-5; author reply 26-7. PubMed ID: 15639670
    [No Abstract]   [Full Text] [Related]  

  • 17. Discontinuation of Vioxx.
    McLean TR
    Lancet; 2005 Jan 1-7; 365(9453):25; author reply 27-8. PubMed ID: 15639673
    [No Abstract]   [Full Text] [Related]  

  • 18. Vioxx: an unequal partnership between safety and efficacy.
    Lancet; 2004 Oct 9-15; 364(9442):1287-8. PubMed ID: 15474114
    [No Abstract]   [Full Text] [Related]  

  • 19. Rofecoxib and the risk of adverse upper gastrointestinal effects.
    Whitney E
    JAMA; 2000 Apr; 283(15):1960; author reply 1961. PubMed ID: 10789660
    [No Abstract]   [Full Text] [Related]  

  • 20. Discontinuation of Vioxx.
    Nutt DJ
    Lancet; 2005 Jan 1-7; 365(9453):28. PubMed ID: 15639676
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.